{
    "root": "26f3b219-18ec-4c4c-86da-6033f6af3185",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Cayston",
    "value": "20250317",
    "ingredients": [],
    "indications": "CAYSTON® is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa. Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia \n                     [see Clinical Studies (14)].\n                  \n                  To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pseudomonas aeruginosa in the lungs.",
    "contraindications": "Administer one dose (one single use vial and one ampule of diluent) 3 times a day for 28 days. ( 2.1 ) Use dose immediately after reconstitution. ( 2.2 ) Administer only with the Altera ® Nebulizer System. Do not administer with any other type of nebulizer. ( 2.3 )",
    "warningsAndPrecautions": "Each kit for a 28-day course of CAYSTON contains 84 sterile vials of CAYSTON and 88 ampules of sterile diluent packed in 2 cartons, each carton containing a 14-day supply. The four additional diluent ampules are provided in case of spillage.\n                  \n                     \n                     \n                     \n                     \n                        \n                           Package Configuration\n                           Dosage Strength\n                           NDC\n                        \n                     \n                     \n                        \n                           28-Day Kit\n                           75 mg\n                           61958-0901-1",
    "adverseReactions": "CAYSTON is contraindicated in patients with a known allergy to aztreonam."
}